

belzutifan film-coated tablets (Welireg®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2684	treatment of adult patients with advanced renal cell carcinoma (RCC) whose disease has progressed on or after treatment with a programmed death receptor-1 (PD-1) /programmed death ligand (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).	Not routinely available as not recommended for use in NHS Scotland	08/09/2025	08/09/2025
Other Decision Specified : Non-submission				
Web Link : https://scottishmedicines.org.uk/media/9430/belzutifan-welireg-non-sub-final-aug-2025-for-website.pdf				
rucaparib film-coated tablets (Rubraca®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2799	as monotherapy for the maintenance treatment of adult patients with advanced (FIGO Stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	08/09/2025	18/11/2025
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9429/rucaparib-rubraca-final-aug-2025-for-website.pdf				

blinatumomab powder for concentrate and solution for solution for infusion (Blinicyto®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2808	for the treatment of adult patients with Philadelphia chromosome negative CD19-positive B-cell precursor acute lymphoblastic leukaemia (ALL) in the consolidation phase. SMC restriction: in the frontline consolidation phase.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	08/09/2025	18/11/2025
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9427/blinatumomab-blinicyto-final-aug-2025-for-website.pdf				
encorafenib hard capsules (Braftovi®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2865	in combination with binimetinib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.	Not routinely available as not recommended for use in NHS Scotland	08/09/2025	08/09/2025
Other Decision Specified : Non-submission				
Web Link : https://scottishmedicines.org.uk/media/9428/encorafenib-braftovi-non-sub-final-aug-2025-for-website.pdf				